Amid growing concerns about healthcare affordability, the United States government has come under increasing pressure to address the high cost of obesity medications. Two major pharmaceutical companies, Novo Nordisk and Eli Lilly, dominate the market with their treatments for obesity and type 2 diabetes. While there have been no formal price reduction agreements between the U.S. government and either company, ongoing policy debates and public scrutiny could influence future negotiations on drug prices.
Key Drugs on the Market
The medications at the centre of this debate include Novo Nordisk’s semaglutide, marketed for diabetes as Ozempic and for obesity as Wegovy, as well as liraglutide under the brand names Victoza (diabetes) and Saxenda (obesity). Eli Lilly’s tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity. These drugs have demonstrated significant effectiveness in weight loss, which has led to surging demand and widespread discussion about their affordability.
Pricing and Accessibility
Despite their proven clinical benefits, these obesity medications remain expensive in the United States, often costing over $1,000 per month without insurance coverage. While the Inflation Reduction Act has granted Medicare the authority to negotiate drug prices for certain medications starting in 2026, GLP-1 drugs for obesity and diabetes are not included in the first wave of drugs subject to negotiation. There have also been no public commitments from Eli Lilly or Novo Nordisk to reduce the prices of their obesity drugs by any set percentage. As a result, many Americans continue to face significant financial barriers in accessing these treatments.
Policy Context and Public Debate
The prevalence of obesity in the United States is now over 42% among adults, contributing to increased risk of heart disease, diabetes, and other costly chronic conditions. Policymakers, advocacy groups, and healthcare experts are calling for reforms to improve drug affordability, especially as new treatments for obesity emerge. Although past presidential administrations, including the Biden administration, have pushed to expand affordable access for essential medications like insulin, the issue of obesity drug prices remains unresolved as of late 2025.
Pharmaceutical Pricing Trends
Rising scrutiny of pharmaceutical pricing, especially for GLP-1 drugs, has prompted broader discussions about healthcare costs and insurance coverage in the United States. While some states and hospitals have explored bulk purchasing or new reimbursement models, these efforts have not led to industry-wide price reductions. Industry analysts note that drug manufacturers rely on profits from high-demand therapies to fund further research and development, complicating efforts to enact sweeping cost controls without risking innovation.
Market Impacts and Future Outlook
Continued public debate and policy initiatives may eventually bring changes to the pricing and availability of obesity drugs. As more Americans seek effective medical treatments for obesity, demand is expected to remain strong, and other pharmaceutical firms are accelerating the development of new options. However, as of November 2025, the United States has not secured any official agreements with Novo Nordisk or Eli Lilly to reduce the prices of their obesity medications.